Evidence map›Paper›PMID 39225160›Full record

ArticleEuropean journal of heart failure2025

Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study.

Arnaud D Kaze, Alain G Bertoni, Ervin R Fox, Michael E Hall, Robert J Mentz, Justin B Echouffo-Tcheugui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arnaud D KazeDepartment of Medicine, Division of Cardiology, Banner-University Medical Center Phoenix, The University of Arizona College of Medicine, Phoenix, AZ, USA.
Alain G BertoniDepartment of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Ervin R FoxDepartment of Medicine, Division of Cardiology, University of Mississippi Medical Center Jackson, Jackson, MS, USA.
Michael E HallDepartment of Medicine, Division of Cardiology, University of Mississippi Medical Center Jackson, Jackson, MS, USA.
Robert J MentzDuke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA.
Justin B Echouffo-TcheuguiDepartment of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-8460-1617

Funding

National Institute on Minority Health and Health Disparities (NIMHD)NHLBI NIH HHS HHSN268201800010INHLBI NIH HHS HHSN268201800011CNHLBI NIH HHS HHSN268201800011INHLBI NIH HHS HHSN268201800012CNHLBI NIH HHS HHSN268201800012INHLBI NIH HHS HHSN268201800014CNHLBI NIH HHS HHSN268201800014INHLBI NIH HHS HHSN268201800015INHLBI NIH HHS K23 HL153774NIMHD NIH HHS HHSN268201800013I
6 · The paper itself

Abstract

aimsThe extent to which metabolic syndrome (MetS) severity influences subclinical myocardial remodelling, heart failure (HF) incidence and subtypes, remains unclear. We assessed the association of MetS with incident HF (including ejection fraction subtypes) among Black individuals. METHODS AND

resultsWe included 4069 Jackson Heart Study participants (mean age 54.4 years, 63.8% women, 37.2% with MetS) without HF. We categorized participants based on MetS status and MetS severity scores (based on waist circumference [MetS-Z-WC] and body mass index [MetS-Z-BMI]). We assessed the associations of MetS indices with echocardiographic parameters, biomarkers of myocardial damage (high-sensitivity cardiac troponin I [hs-cTnI] and B-type natriuretic peptide [BNP]) and incident HF hospitalizations including HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF). MetS severity was associated with subclinical cardiac remodelling (assessed by echocardiographic measures and biomarkers of myocardial damage). Over a median of 12 years, 319 participants developed HF (157 HFpEF, 149 HFrEF and 13 HF of unknown type). MetS was associated with a twofold greater risk of HF (hazard ratio [HR] 2.07, 95% confidence interval [CI] 1.64-2.61). Compared to the lowest quartile (Q1) of MetS-Z-WC, the highest quartile (Q4) conferred a higher risk of HF (HR 2.35, 95% CI 1.67-3.30), with a stronger association for HFpEF (Q4 vs. Q1: HR 4.94, 95% CI 2.67-9.14) vs. HFrEF (HR 1.69, 95% CI 1.06-2.70).

conclusionsMetabolic syndrome severity was associated with both HF subtypes among Black individuals, highlighting the importance of optimal metabolic health for preventing HF.

Indexed as

Black or African AmericanHeart FailureMetabolic SyndromeAgedBiomarkersBody Mass IndexEchocardiographyFemaleHumansIncidenceMaleMiddle AgedMississippiNatriuretic Peptide, BrainRisk FactorsSeverity of Illness IndexBiomarkersNatriuretic Peptide, BrainHeart failureMetabolic syndromeMetabolic syndrome severityOutcomesRisk

Identifiers

PMID39225160
PMCPMC11873178

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.